Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01782027 · ClinicalTrials.gov registry record · NA
Mendelian Reverse Cholesterol Transport Study
A NA study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT01782027: Clinical Trial NA study, sponsored by University of Pennsylvania.
NCT01782027 is a NA study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01782027, a NA study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the use of radiolabeled particulate cholesterol administered intravenously in association with albumin, as a method to study reverse cholesterol transport (RCT) in people carrying mutations in genes known to affect high density lipoprotein (HDL) metabolism by analyzing changes in the tracer activity in total plasma, lipoproteins fractions and feces.
Interventions
- DRUG 3H-cholesterol bound to albumin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-10 |
| Est. Completion | 2024-09-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01782027
The ClinicalTrials.gov registry entry for NCT01782027 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 3H-cholesterol bound to albumin is the first listed.
NCT01782027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01782027 about?
NCT01782027 is a clinical study titled "Mendelian Reverse Cholesterol Transport Study". The purpose of this study is to investigate the use of radiolabeled particulate cholesterol administered intravenously in association with albumin, as a method to study reverse cholesterol transport (RCT) in people carrying mutations in genes known to affect high density lipoprotein (HDL) metabolism...
What is the current status of trial NCT01782027?
This trial is currently terminated. It is a NA study. The enrollment target is 17 participants. The study started on 2012-10. Estimated completion is 2024-09-04.
What interventions are being tested in trial NCT01782027?
The interventions under investigation include: 3H-cholesterol bound to albumin (DRUG).
Who is sponsoring clinical trial NCT01782027?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.